-
Anti Reverse Cap Analog for Synthetic mRNA
2026-08-18
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, enables orientation-specific 5′ capping for higher-performing synthetic mRNA workflows. Its strongest use cases include transient transcription-factor delivery, cell reprogramming, gene-editing research, and assays where translation output must be separated from delivery or cell-state effects.
-
Anti Reverse Cap Analog for High-Yield mRNA
2026-08-17
Anti Reverse Cap Analog improves synthetic mRNA performance by enforcing productive cap orientation during in vitro transcription. This guide connects cap selection with reproducible expression assays, metabolic studies, and troubleshooting for mRNA therapeutics research.
-
Deferoxamine Mesylate in Ferroptosis Assays
2026-08-17
Deferoxamine mesylate is more than an iron-chelating agent: it is a practical tool for separating iron dependence, oxidative stress, and hypoxia signaling in cell assays. This guide translates ferroptosis research into better controls, exposure designs, and interpretation strategies.
-
Protease Inhibitor Cocktail for TBI Protein Workflows
2026-08-16
Learn how an EDTA-free, 100X formulation protects PFKFB3, glycolytic enzymes, and signaling complexes during traumatic brain injury protein workflows. Practical dilution guidance, assay-specific controls, and troubleshooting help preserve samples for Western blotting, co-immunoprecipitation, kinase assays, and related applications.
-
CCCP Workflows for Mitochondrial Assays
2026-08-15
CCCP enables controlled mitochondrial proton gradient disruption for live-cell imaging, bioenergetic stress testing, and orthogonal validation of patient-derived models. This practical guide connects carbonyl cyanide m-chlorophenyl hydrazine with urine-derived stem cell research, AI-based morphology analysis, and reproducible troubleshooting.
-
Esflurbiprofen and SERT–nNOS Fast Antidepressant Action
2026-08-14
The reference study identifies esflurbiprofen as a fast-onset antidepressant candidate by screening for compounds that disrupt the SERT–nNOS complex in the dorsal raphe nucleus. Its combined molecular, behavioral, and rs-fMRI evidence supports a mechanism in which altered serotonin transporter localization reduces autoreceptor-mediated inhibition and restores serotonergic signaling.
-
MCRS1 Enhances MHC-I–Dependent Tumor Immunity
2026-08-14
The reference study identifies MCRS1 as a transcriptional regulator that increases MHC-I expression and sensitizes pancreatic tumors to T cell–mediated killing and α-PD-1 therapy. Its CRISPR activation, mechanistic, animal, and patient-level evidence connects chromatin regulation with tumor antigen presentation, while also highlighting practical requirements for preserving protein integrity in related validation workflows.
-
Protease Inhibitor Cocktail for p53 Assays
2026-08-13
Discover how a Protease Inhibitor Cocktail can preserve fragile p53-Y220C samples without chelating divalent cations. This guide connects protein extraction protease inhibitor selection with structure-guided mutant-p53 reactivation assays and practical interpretation of degradation-sensitive data.
-
Lassa Virus Spike Conformational Changes and Inhibition
2026-08-13
Katz et al. define how endosomal acidification reshapes the Lassa virus spike before membrane fusion, linking early transmembrane remodeling to later receptor release and spike opening. Their structure-guided analysis of ARN-75039 provides a molecular explanation for entry inhibition and identifies conformational transitions that may guide antiviral research.
-
Vardenafil HCl Trihydrate: Assay Guide
2026-08-12
This scenario-based guide explains how Vardenafil HCl Trihydrate (SKU A4323) can support interpretable PDE5, cGMP, proliferation, and cytotoxicity experiments. It focuses on concentration logic, solvent compatibility, assay controls, proteoform-aware interpretation, and practical product-selection criteria.
-
Lassa Virus Spike: pH-Driven Entry and Inhibition
2026-08-12
The reference study maps how acidification reorganizes the Lassa virus spike before membrane fusion, identifying early transmembrane changes, pH-sensitive metal coordination, and later spike opening that promotes receptor release. Structural analysis combined with functional inhibition by ARN-75039 provides a mechanistic framework for understanding LASV entry and targeting related viral fusion processes.
-
Protease Inhibitor Cocktail for HepaRG Assays
2026-08-11
Learn how a Protease Inhibitor Cocktail can protect HepaRG-derived proteins without chelating divalent cations. This guide connects protease control to HBV/HDV assay design, differentiation state, and interpretation of biochemical endpoints.
-
Radioiodinated Balsalazide for UC Imaging in Mice
2026-08-11
Sanad et al. developed and evaluated radioiodinated balsalazide as a colon-directed tracer for ulcerative colitis in mice. The optimized chloramine-T labeling workflow produced a stable radiotracer and showed markedly elevated uptake in ulcerated colon, supporting its use for preclinical biodistribution and inflammatory bowel disease model studies.
-
OTUD3-SLC7A11 Drives Ferroptosis Resistance in ccRCC
2026-08-10
The 2025 Cancer Letters study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, lowers oxidative pressure, and enables clear cell renal cell carcinoma cells to resist sunitinib-induced ferroptosis. Its mechanistic framework links protein turnover to cystine metabolism and suggests that OTUD3–SLC7A11 activity may be a useful therapeutic and biomarker axis for studying tyrosine kinase inhibitor resistance.
-
ZNF263–ULK1 Autophagy Axis in ICC
2026-08-09
Yan and colleagues identify ZNF263 as a transcriptional driver of intrahepatic cholangiocarcinoma (ICC) proliferation and connect its activity to enhancer-mediated activation of ULK1 and autophagy. By combining clinical tissue analysis, genomic profiling, reporter validation, cellular assays, and xenograft experiments, the study provides a mechanistic framework for interpreting ZNF263 as a potential prognostic or therapeutic target.